Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sleeping Beauty TCR-T
- Development stage
- Unknown
- Lead developer
- Alaunos Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Sleeping Beauty TCR-T is an autologous, non-viral T-cell receptor (TCR) engineered T-cell therapy. It utilizes the Sleeping Beauty (SB) transposon/transposase system, a DNA-based gene transfer method, to introduce tumor-specific TCRs into a patient's T cells. This approach avoids the use of viral vectors (such as lentivirus or retrovirus), potentially reducing manufacturing complexity and cost. The therapy targets specific driver mutations (neoantigens) in genes such as KRAS, TP53, and EGFR, which are presented by specific Human Leukocyte Antigen (HLA) molecules on the surface of cancer cells. Developed through a collaboration between the National Cancer Institute (NCI) and Alaunos Therapeutics (formerly Ziopharm Oncology), it is currently being evaluated in Phase 1/2 clinical trials for various solid tumors, including colorectal, pancreatic, and non-small cell lung cancers.
- Other names
- Sleeping Beauty-engineered TCR-T cellsAlaunos TCR-TZiopharm TCR-T
02
Targets
Mutant tumor protein p53-derived neoantigen peptides presented by human leukocyte antigen (HLA) class I allelesMutant Epidermal Growth Factor Receptor-derived neoantigen peptide-HLA class I complexpMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Sleeping Beauty TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sleeping Beauty TCR-T.